Risk factors for hyperglycemia in extremely low birth weight infants during the first 14 days.


Journal

Pediatrics and neonatology
ISSN: 2212-1692
Titre abrégé: Pediatr Neonatol
Pays: Singapore
ID NLM: 101484755

Informations de publication

Date de publication:
01 2022
Historique:
received: 17 03 2021
revised: 17 05 2021
accepted: 05 07 2021
pubmed: 1 8 2021
medline: 25 3 2022
entrez: 31 7 2021
Statut: ppublish

Résumé

There are limited data regarding the risk factors for hyperglycemia in extremely low birth weight infants (ELBWIs). The aim of this observational study was to investigate the incidence of hyperglycemia among ELBWIs during the first 14 days of life and identify independent risk factors for hyperglycemia development. We retrospectively evaluated 55 ELBWIs (32 male infants) between January 2015 and March 2020. Hyperglycemia was diagnosed when the glucose level was ≥180 mg/dL. Demographic and clinical data were extracted from the patients' medical records. The risk factors associated with the onset of hyperglycemia were identified by Cox proportional hazards regression analysis with variables that had previously been identified as risk factors for hyperglycemia. Hyperglycemia developed in 23 patients (41.8%) within the first 14 days of life. Gestational age, chorioamnionitis, postnatal intravenous glucocorticoids, and probiotic type were included in the analysis. The results indicated that hyperglycemia was significantly associated with gestational age (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.48-0.87; P = 0.004). Further, Bifidobacterium breve (B. breve M-16V) use was related to hyperglycemia in ELBWIs (HR, 2.95; 95% CI, 1.10-7.87; P = 0.031). Hyperglycemia was strongly associated with lower gestational age and B. breve M-16V use in our study population. Although probiotic supplementation may be beneficial for preterm infants to reduce the incidence of necrotizing enterocolitis, the dextrin used as an excipient in B. breve M-16V may lead to an undesirable carbohydrate load in ELBWIs.

Sections du résumé

BACKGROUND
There are limited data regarding the risk factors for hyperglycemia in extremely low birth weight infants (ELBWIs). The aim of this observational study was to investigate the incidence of hyperglycemia among ELBWIs during the first 14 days of life and identify independent risk factors for hyperglycemia development.
METHODS
We retrospectively evaluated 55 ELBWIs (32 male infants) between January 2015 and March 2020. Hyperglycemia was diagnosed when the glucose level was ≥180 mg/dL. Demographic and clinical data were extracted from the patients' medical records. The risk factors associated with the onset of hyperglycemia were identified by Cox proportional hazards regression analysis with variables that had previously been identified as risk factors for hyperglycemia.
RESULTS
Hyperglycemia developed in 23 patients (41.8%) within the first 14 days of life. Gestational age, chorioamnionitis, postnatal intravenous glucocorticoids, and probiotic type were included in the analysis. The results indicated that hyperglycemia was significantly associated with gestational age (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.48-0.87; P = 0.004). Further, Bifidobacterium breve (B. breve M-16V) use was related to hyperglycemia in ELBWIs (HR, 2.95; 95% CI, 1.10-7.87; P = 0.031).
CONCLUSION
Hyperglycemia was strongly associated with lower gestational age and B. breve M-16V use in our study population. Although probiotic supplementation may be beneficial for preterm infants to reduce the incidence of necrotizing enterocolitis, the dextrin used as an excipient in B. breve M-16V may lead to an undesirable carbohydrate load in ELBWIs.

Identifiants

pubmed: 34330686
pii: S1875-9572(21)00129-7
doi: 10.1016/j.pedneo.2021.07.001
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

13-18

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Yuka Inage (Y)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Daishi Hirano (D)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. Electronic address: bqx1976@hotmail.com.

Ai Nakagawa (A)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Saya Yamada (S)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Yuko Kotake (Y)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Naohiro Ikoma (N)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Kensuke Kumazawa (K)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Shion Hayashi (S)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Yukitoshi Tanabe (Y)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Masahisa Kobayashi (M)

Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Masaki Shimizu (M)

Division of Neonatology, Saitama Children's Medical Center, Saitama-City, Saitama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH